ROSE Stock Overview
Instituto Rosenbusch S.A. markets and manufactures veterinary products in Argentina.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Instituto Rosenbusch S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AR$110.75 |
| 52 Week High | AR$135.00 |
| 52 Week Low | AR$14.00 |
| Beta | 0.064 |
| 1 Month Change | -2.21% |
| 3 Month Change | 9.65% |
| 1 Year Change | 661.17% |
| 3 Year Change | 1,103.80% |
| 5 Year Change | 1,770.78% |
| Change since IPO | 35,412.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROSE | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 28.0% | 1.9% | 14.3% |
| 1Y | 661.2% | -15.2% | 370.0% |
Return vs Industry: ROSE exceeded the AR Pharmaceuticals industry which returned -15.2% over the past year.
Return vs Market: ROSE exceeded the AR Market which returned 370% over the past year.
Price Volatility
| ROSE volatility | |
|---|---|
| ROSE Average Weekly Movement | 17.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AR Market | 13.5% |
| 10% least volatile stocks in AR Market | 7.7% |
Stable Share Price: ROSE's share price has been volatile over the past 3 months.
Volatility Over Time: ROSE's weekly volatility has increased from 12% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | n/a | Rodolfo Martín Balestrini | www.rosenbusch.com |
Instituto Rosenbusch S.A. markets and manufactures veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals.
Instituto Rosenbusch S.A. Fundamentals Summary
| ROSE fundamental statistics | |
|---|---|
| Market cap | AR$4.72b |
| Earnings (TTM) | AR$562.94m |
| Revenue (TTM) | AR$4.53b |
8.4x
P/E Ratio1.0x
P/S RatioIs ROSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROSE income statement (TTM) | |
|---|---|
| Revenue | AR$4.53b |
| Cost of Revenue | AR$3.23b |
| Gross Profit | AR$1.30b |
| Other Expenses | AR$734.16m |
| Earnings | AR$562.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.22 |
| Gross Margin | 28.65% |
| Net Profit Margin | 12.43% |
| Debt/Equity Ratio | 49.5% |
How did ROSE perform over the long term?
See historical performance and comparison